Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has shared an announcement.
Biocytogen Pharmaceuticals has established a Nomination Committee under its board of directors to regulate the employment and appointment of senior management. This move aims to improve the company’s governance and competitiveness, with the committee responsible for recommending candidates and selection criteria for senior roles, ensuring a majority of independent directors and gender diversity.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative biopharmaceutical products. The company is committed to enhancing its core competitiveness and optimizing its corporate governance structure.
Average Trading Volume: 411,768
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.84B
For detailed information about 2315 stock, go to TipRanks’ Stock Analysis page.